Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 3.02

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer (2010) 1.00

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer (2011) 0.99

Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie (2007) 0.92

Response assessment in metronomic chemotherapy: RECIST or PERCIST? Indian J Nucl Med (2014) 0.87

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs (2011) 0.82

Current achievements and future perspectives of metronomic chemotherapy. Invest New Drugs (2016) 0.75

Ventral and dorsal pathways for language. Proc Natl Acad Sci U S A (2008) 4.32

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol (2003) 4.29

Genetically determined differences in learning from errors. Science (2007) 4.04

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00

Time-resolved 3D MR velocity mapping at 3T: improved navigator-gated assessment of vascular anatomy and blood flow. J Magn Reson Imaging (2007) 2.93

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res (2012) 2.78

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70

Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol (2012) 2.45

Cortical and subcortical correlates of electroencephalographic alpha rhythm modulation. J Neurophysiol (2004) 2.09

Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry (2005) 2.08

Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol (2008) 2.06

Experimental analysis of parallel excitation using dedicated coil setups and simultaneous RF transmission on multiple channels. Magn Reson Med (2005) 2.03

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol (2008) 1.98

The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs (2005) 1.75

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology (2011) 1.69

Fluid-dynamic modeling of the human left ventricle: methodology and application to surgical ventricular reconstruction. Ann Thorac Surg (2009) 1.66

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer (2005) 1.54

Fast multiecho balanced SSFP metabolite mapping of (1)H and hyperpolarized (13)C compounds. MAGMA (2009) 1.50

4D phase contrast MRI at 3 T: effect of standard and blood-pool contrast agents on SNR, PC-MRA, and blood flow visualization. Magn Reson Med (2010) 1.49

Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry (2003) 1.48

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem (2002) 1.48

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res (2002) 1.46

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45

Reconstruction of MRI data encoded with arbitrarily shaped, curvilinear, nonbijective magnetic fields. Magn Reson Med (2010) 1.44

Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. Onkologie (2009) 1.44

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer (2005) 1.42

Chronic insomnia and MRI-measured hippocampal volumes: a pilot study. Sleep (2007) 1.38

Detailed analysis of myocardial motion in volunteers and patients using high-temporal-resolution MR tissue phase mapping. J Magn Reson Imaging (2006) 1.38

Simultaneously driven linear and nonlinear spatial encoding fields in MRI. Magn Reson Med (2010) 1.36

Is TrueFISP a gradient-echo or a spin-echo sequence? Magn Reson Med (2003) 1.35

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32

Time-resolved, 3-dimensional magnetic resonance flow analysis at 3 T: visualization of normal and pathological aortic vascular hemodynamics. J Comput Assist Tomogr (2007) 1.30

Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J Infect Dis (2010) 1.30

Three-dimensional analysis of segmental wall shear stress in the aorta by flow-sensitive four-dimensional-MRI. J Magn Reson Imaging (2009) 1.29

Variation in the serotonin transporter gene modulates selective attention to threat. Emotion (2008) 1.28

Navigator accuracy requirements for prospective motion correction. Magn Reson Med (2010) 1.26

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23

Tracking dynamic resting-state networks at higher frequencies using MR-encephalography. Neuroimage (2012) 1.22

Identification of first candidate genes for creativity: a pilot study. Brain Res (2006) 1.21

Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett (2006) 1.20

Advantages and limitations of prospective head motion compensation for MRI using an optical motion tracking device. Acad Radiol (2006) 1.18

In vivo wall shear stress distribution in the carotid artery: effect of bifurcation geometry, internal carotid artery stenosis, and recanalization therapy. Circ Cardiovasc Imaging (2010) 1.17

Highly k-t-space-accelerated phase-contrast MRI. Magn Reson Med (2008) 1.17

Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke. Stroke (2010) 1.16

Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging (2009) 1.15

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15

Single-breathhold 3D-trueFISP cine cardiac imaging. Magn Reson Med (2002) 1.14

Toward biocompatible nuclear hyperpolarization using signal amplification by reversible exchange: quantitative in situ spectroscopy and high-field imaging. Anal Chem (2014) 1.14

Structural connectivity for visuospatial attention: significance of ventral pathways. Cereb Cortex (2010) 1.13

Investigating myocardial motion by MRI using tissue phase mapping. Eur J Cardiothorac Surg (2006) 1.13

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol (2005) 1.13

Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry (2008) 1.13

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res (2007) 1.12

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol (2002) 1.10

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol (2009) 1.10

Morphometry of the retrobulbar human optic nerve: comparison between conventional sonography and ultrafast magnetic resonance sequences. Invest Ophthalmol Vis Sci (2007) 1.10

Localization by nonlinear phase preparation and k-space trajectory design. Magn Reson Med (2011) 1.10

Navigator gated high temporal resolution tissue phase mapping of myocardial motion. Magn Reson Med (2006) 1.09

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res (2004) 1.09

Dental MRI: imaging of soft and solid components without ionizing radiation. J Magn Reson Imaging (2012) 1.08

In vivo assessment of wall shear stress in the atherosclerotic aorta using flow-sensitive 4D MRI. Magn Reson Med (2010) 1.08

Time-resolved magnetic resonance angiography and flow-sensitive 4-dimensional magnetic resonance imaging at 3 Tesla for blood flow and wall shear stress analysis. J Thorac Cardiovasc Surg (2008) 1.07

Multidirectional flow analysis by cardiovascular magnetic resonance in aneurysm development following repair of aortic coarctation. J Cardiovasc Magn Reson (2008) 1.06

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol (2004) 1.05

Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat (2003) 1.05

Magnetic resonance tissue phase mapping of myocardial motion: new insight in age and gender. Circ Cardiovasc Imaging (2009) 1.04

Retrograde embolism from the descending aorta: visualization by multidirectional 3D velocity mapping in cryptogenic stroke. Stroke (2009) 1.04

Insomnia does not appear to be associated with substantial structural brain changes. Sleep (2013) 1.03

A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res (2003) 1.02

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther (2012) 1.02

Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci (2011) 1.01